Skip to main content
Erschienen in: International Journal of Hematology 6/2023

12.09.2023 | Case Report

Leukemic-phase mucosa-associated lymphoid tissue lymphoma

verfasst von: Takayuki Yotsuyanagi, Naoto Tomita, Yusuke Saiki, Akiko Uchida, Yu Uemura, Yoshinori Suzuki, Tsuneaki Hirakawa, Masayuki Kato, Naoya Nakamura, Ayako Arai

Erschienen in: International Journal of Hematology | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

A 78-year-old man presenting with leukocytosis was admitted to our hospital. The patient was asymptomatic and showed no lymphadenopathy. Peripheral blood flow cytometry revealed a leukemic-phase B-cell lymphoma with medium-to-large abnormal cells with reticulum. Positron emission tomography/computed tomography revealed abnormal uptake in the right orbit, bone marrow, and spleen. We performed immunological staining and fluorescence in situ hybridization on tissues extracted from the right orbit and bone marrow, which led to the diagnosis of mucosa-associated lymphoid tissue (MALT) lymphoma. Polymerase chain reaction analysis of immunoglobulin heavy chain rearrangements in the right orbital mass and bone marrow suggested that they were identical clones. Based on these collective findings, the diagnosis of leukemic-phase MALT lymphoma was confirmed, with sites of involvement including the bone marrow, peripheral blood, right orbit, and spleen. This is a highly rare case of leukemic MALT lymphoma.
Literatur
1.
Zurück zum Zitat Cook JR, Isaacson PG, Chott A, Nakamura S, Muller-Hermelink HK, Harris NL, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow SH, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2017. p. 259–62. Cook JR, Isaacson PG, Chott A, Nakamura S, Muller-Hermelink HK, Harris NL, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow SH, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2017. p. 259–62.
2.
Zurück zum Zitat Guidoboni M, Ferreri AJ, Ponzoni M, Doglioni C, Dolcetti R. Infectious agents in mucosa-associated lymphoid tissue-type lymphomas: pathogenic role and therapeutic perspectives. Clin Lymphoma Myeloma. 2006;6:289–300.CrossRefPubMed Guidoboni M, Ferreri AJ, Ponzoni M, Doglioni C, Dolcetti R. Infectious agents in mucosa-associated lymphoid tissue-type lymphomas: pathogenic role and therapeutic perspectives. Clin Lymphoma Myeloma. 2006;6:289–300.CrossRefPubMed
3.
Zurück zum Zitat Kiesewetter B, Raderer M. Immunomodulatory treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma). Hematol Oncol. 2020;38:417–24.CrossRefPubMed Kiesewetter B, Raderer M. Immunomodulatory treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma). Hematol Oncol. 2020;38:417–24.CrossRefPubMed
4.
Zurück zum Zitat Ishii Y, Tomita N, Suzuki T, Ishiyama Y, Kishimoto K, Yamamoto E, et al. Dissemination pattern of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. Leuk Lymphoma. 2015;56:2750–2.CrossRefPubMed Ishii Y, Tomita N, Suzuki T, Ishiyama Y, Kishimoto K, Yamamoto E, et al. Dissemination pattern of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. Leuk Lymphoma. 2015;56:2750–2.CrossRefPubMed
5.
Zurück zum Zitat Reitter S, Neumeister P, Beham-Schmid C, Emberger W, Strunk D, Brezinschek R, et al. A case of generalized MALT lymphoma with IgM paraproteinemia and peripheral blood involvement. Ann Hematol. 2010;89:213–4.CrossRefPubMed Reitter S, Neumeister P, Beham-Schmid C, Emberger W, Strunk D, Brezinschek R, et al. A case of generalized MALT lymphoma with IgM paraproteinemia and peripheral blood involvement. Ann Hematol. 2010;89:213–4.CrossRefPubMed
6.
Zurück zum Zitat Griesser H, Kaiser U, Augener W, Tiemann M, Lennert K. B-cell lymphoma of the mucosa-associated lymphatic tissue (MALT) presenting with bone marrow and peripheral blood involvement. Leuk Res. 1990;14:617–22.CrossRefPubMed Griesser H, Kaiser U, Augener W, Tiemann M, Lennert K. B-cell lymphoma of the mucosa-associated lymphatic tissue (MALT) presenting with bone marrow and peripheral blood involvement. Leuk Res. 1990;14:617–22.CrossRefPubMed
7.
Zurück zum Zitat Thieblemont C, Bastion Y, Berger F, Rieux C, Salles G, Dumontet C, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol. 1997;15:1624–30.CrossRefPubMed Thieblemont C, Bastion Y, Berger F, Rieux C, Salles G, Dumontet C, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol. 1997;15:1624–30.CrossRefPubMed
8.
Zurück zum Zitat Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist. 2006;11:285–91.CrossRefPubMed Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist. 2006;11:285–91.CrossRefPubMed
9.
Zurück zum Zitat Raderer M, Vorbeck F, Formanek M, Osterreicher C, Valencak J, Penz M, et al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer. 2000;83:454–7.CrossRefPubMedPubMedCentral Raderer M, Vorbeck F, Formanek M, Osterreicher C, Valencak J, Penz M, et al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer. 2000;83:454–7.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat de Boer JP, Hiddink RF, Raderer M, Antonini N, Aleman BM, Boot H, et al. Dissemination patterns in non-gastric MALT lymphoma. Haematologica. 2008;93:201–6.CrossRefPubMed de Boer JP, Hiddink RF, Raderer M, Antonini N, Aleman BM, Boot H, et al. Dissemination patterns in non-gastric MALT lymphoma. Haematologica. 2008;93:201–6.CrossRefPubMed
11.
12.
Zurück zum Zitat Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983;52:1410–6.CrossRefPubMed Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983;52:1410–6.CrossRefPubMed
13.
Zurück zum Zitat Garcia DP, Rooney MT, Ahmad E, Davis BH. Diagnostic usefulness of CD23 and FMC-7 antigen expression patterns in B-cell lymphoma classification. Am J Clin Pathol. 2001;115:258–65.CrossRefPubMed Garcia DP, Rooney MT, Ahmad E, Davis BH. Diagnostic usefulness of CD23 and FMC-7 antigen expression patterns in B-cell lymphoma classification. Am J Clin Pathol. 2001;115:258–65.CrossRefPubMed
14.
Zurück zum Zitat Tandon B, Peterson L, Gao J, Nelson B, Ma S, Rosen S, et al. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas. Mod Pathol. 2011;24:1433–43.CrossRefPubMed Tandon B, Peterson L, Gao J, Nelson B, Ma S, Rosen S, et al. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas. Mod Pathol. 2011;24:1433–43.CrossRefPubMed
15.
Zurück zum Zitat Soliman DS, Al-Kuwari E, Siveen KS, Al-Abdulla R, Chandra P, Yassin M, et al. Downregulation of Lymphoid enhancer-binding factor 1 (LEF-1) expression (by immunohistochemistry and/ flow cytometry) in chronic lymphocytic leukemia with atypical immunophenotypic and cytologic features. Int J Lab Hematol. 2021;43:515–25.CrossRefPubMed Soliman DS, Al-Kuwari E, Siveen KS, Al-Abdulla R, Chandra P, Yassin M, et al. Downregulation of Lymphoid enhancer-binding factor 1 (LEF-1) expression (by immunohistochemistry and/ flow cytometry) in chronic lymphocytic leukemia with atypical immunophenotypic and cytologic features. Int J Lab Hematol. 2021;43:515–25.CrossRefPubMed
16.
Zurück zum Zitat Kanellis G, Roncador G, Arribas A, Mollejo M, Montes-Moreno S, Maestre L, et al. Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia. 2009;23:1847–57.CrossRefPubMed Kanellis G, Roncador G, Arribas A, Mollejo M, Montes-Moreno S, Maestre L, et al. Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia. 2009;23:1847–57.CrossRefPubMed
17.
Zurück zum Zitat Raimbault A, Machherndl-Spandl S, Itzykson R, Clauser S, Chapuis N, Mathis S, et al. CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation. Br J Haematol. 2019;184:625–33.CrossRefPubMed Raimbault A, Machherndl-Spandl S, Itzykson R, Clauser S, Chapuis N, Mathis S, et al. CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation. Br J Haematol. 2019;184:625–33.CrossRefPubMed
18.
Zurück zum Zitat Darom A, Gomatos IP, Leandros E, Xatziyiannis E, Fotiadis C, Konstadoulakis MM. HLA-DR antigen and Bax protein expression in patients with primary non-Hodgkin’s gastric lymphoma. Hybrid Hybridomics. 2004;23:87–92.CrossRefPubMed Darom A, Gomatos IP, Leandros E, Xatziyiannis E, Fotiadis C, Konstadoulakis MM. HLA-DR antigen and Bax protein expression in patients with primary non-Hodgkin’s gastric lymphoma. Hybrid Hybridomics. 2004;23:87–92.CrossRefPubMed
19.
Zurück zum Zitat Ferry JA, Yang WI, Zukerberg LR, Wotherspoon AC, Arnold A, Harris NL. CD5+ extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol. 1996;105:31–7.CrossRefPubMed Ferry JA, Yang WI, Zukerberg LR, Wotherspoon AC, Arnold A, Harris NL. CD5+ extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol. 1996;105:31–7.CrossRefPubMed
20.
Zurück zum Zitat Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95:802–6.CrossRefPubMed Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95:802–6.CrossRefPubMed
21.
Zurück zum Zitat Sretenovic M, Colovic M, Jankovic G, Suvajdzic N, Mihaljevic B, Colovic N, et al. More than a third of non-gastric malt lymphomas are disseminated at diagnosis: a single center survey. Eur J Haematol. 2009;82:373–80.CrossRefPubMed Sretenovic M, Colovic M, Jankovic G, Suvajdzic N, Mihaljevic B, Colovic N, et al. More than a third of non-gastric malt lymphomas are disseminated at diagnosis: a single center survey. Eur J Haematol. 2009;82:373–80.CrossRefPubMed
Metadaten
Titel
Leukemic-phase mucosa-associated lymphoid tissue lymphoma
verfasst von
Takayuki Yotsuyanagi
Naoto Tomita
Yusuke Saiki
Akiko Uchida
Yu Uemura
Yoshinori Suzuki
Tsuneaki Hirakawa
Masayuki Kato
Naoya Nakamura
Ayako Arai
Publikationsdatum
12.09.2023
Verlag
Springer Nature Singapore
Erschienen in
International Journal of Hematology / Ausgabe 6/2023
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-023-03654-3

Weitere Artikel der Ausgabe 6/2023

International Journal of Hematology 6/2023 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.